GLP-1 Crackdown: What the FDA Really Means & Why Compounding Still Matters
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
GLP-1 Crackdown: What the FDA Really Means & Why Compounding Still Matters
-
Narrated by:
-
By:
About this listen
There’s been a lot of noise lately around semaglutide, tirzepatide, and other GLP-1 medications—especially as the FDA cracks down on certain compounded versions. But what’s really going on? And what should patients and providers know?
In this solo episode, I unpack the truth behind the headlines. We’ll clarify what GLP-1 medications actually are (hint: they’re not insulin), why they’re in such high demand, and how compounding pharmacies legally stepped in during national shortages. I’ll also break down the difference between 503A and 503B pharmacies and share how to spot quality in compounded meds.
Whether you’re a patient, provider, or pharmacy pro, this episode clears the fog around GLP-1s and gives you real tools to stay informed.
What listeners say about GLP-1 Crackdown: What the FDA Really Means & Why Compounding Still Matters
Average Customer RatingsReviews - Please select the tabs below to change the source of reviews.
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.